Chugai Pharmaceutical Co., Ltd. announced that it
obtained approval from the Ministry of Health, Labour and Welfare on
September 2, 2015 for “Alecensa® Capsule 150mg,” a high content preparation of the ALK inhibitor “Alecensa® Capsule 20mg and 40mg” (generic name: alectinib hydrochloride) sold for the indication of "ALK
fusion gene positive unresectable, advanced/recurrent non-small cell
lung cancer." Following its National Health Insurance Drug Price listing
on November 28, we launch the “Alecensa® Capsule 150mg” today.
Regarding Alecensa, the patients have been obliged to orally take in
total of 8 capsules (7 capsules of 40mg preparation and 1 capsule of
20mg preparation) per time, twice daily. Considering great need of a
high content preparation to improve convenience of patients, Chugai
started developing a 150mg preparation and filed an application in
September 2014.
